Results 211 to 220 of about 25,833,379 (292)

Primary Central Nervous System Lymphoma With Testicular and Prostatic Involvement: A Case Report. [PDF]

Cureus
Rodríguez Morales JA, Murguía Salgado V, Barajas López V, Alvarez Salinas A, Amador LF.   +4 more
europepmc   +1 more source

CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib-Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET-CT. [PDF]

Am J Hematol
Sheng L, Hu H, Lai Y, Wang S, Wang D, Tang S, Xu K, Sun Y, Zhang P, Lai B, Hu L, Chen L, Pan Y, Nie S, Gao X, Fan L, Ouyang G.   +16 more
europepmc   +1 more source

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma. [PDF]

Future Oncol
Nayak L, Grommes C, Psoinos C, Reu FJ, Takazawa A, Uttarwar M, Xia B, Carvajal LA, Kim S, Sherman ML, Batchelor TT.   +10 more
europepmc   +1 more source

Toxicity of Cytarabine Intravenous Constant Rate Infusion in Cats With Lymphoma

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Cytarabine intravenous constant rate infusion (IV CRI) toxicity in cats with lymphoma has not been well documented. We aimed to assess toxicities following cytarabine IV CRI as a single‐agent or within a multiagent protocol in cats with lymphoma. Medical records of cats with lymphoma treated with cytarabine IV CRI, with documented dose, route,
Rachel Hanford, Katherine A. Skorupski, Robert B. Rebhun, Rachel V. Brady, Sami Al‐Nadaf, Amandine T. Lejeune   +5 more
wiley   +1 more source

Utility of various positron emission tomography tracers in differentiating primary central nervous system lymphoma from glioblastoma multiforme. [PDF]

EJNMMI Rep
Kawai N, Miyatake N, Suzuki K, Ogawa D, Hatakeyama T, Nishiyama Y, Miyake K.   +6 more
europepmc   +1 more source

Quality of Life Shapes Owner Decision‐Making in Canine Cancer Care: Insights From Large‐Scale Online Discourse

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Canine cancer imposes substantial emotional, financial and decisional burden on owners navigating complex referral pathways and treatment options. Understanding how owners experience and interpret these pathways is essential to improving care delivery.
Georgina Anne Tarrant, Andi Flory, Taranpreet Singh Rai, Andrea Wright, Travis Lee Street, Kevin Wells   +5 more
wiley   +1 more source

The Regulation of Vasomotor and Cardiorespiratory Pulsations Is Disrupted in Primary Central Nervous System Lymphoma: A Case-Control fMRI Study. [PDF]

Hum Brain Mapp
Poltojainen V, Järvelä M, Keinänen N, Bode MK, Isokangas JM, Kuitunen H, Nikkinen J, Korhonen V, Huotari N, Raitamaa L, Kananen J, Helakari H, Korhonen TK, Tetri S, Kuittinen O, Kiviniemi V.   +15 more
europepmc   +1 more source

Hypoxia and the cytoskeleton

The Journal of Physiology, EarlyView.
Abstract figure legend Schematic outlining the activation of hypoxia‐sensitive pathways, the influence of hypoxia and associated pathways on the cytoskeleton, and the impact of these on disease progression. Abstract A highly‐regulated and dynamic cytoskeleton is vital for functional cellular physiology and the maintenance of homeostasis.
Darragh Flood, Cormac T. Taylor
wiley   +1 more source

Soluble TIM-3 and galectin-9 serve as additional diagnostic biomarkers in primary central nervous system lymphoma. [PDF]

J Neurol
Nishii S, Akatani R, Shiroma K, Takeda R, Tsuji A, Katanazaka K, Matoba K, Otani M, Koto S, Tanaka K, Nagashima H, Sekiguchi K, Sasayama T, Chihara N.   +13 more
europepmc   +1 more source

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source